Assess whether biosimilarity is analytically justified (0d2db9)

Situation

Pharmacovigilance work in an RWE group proposing a post-marketing study instead of a new RCT now turns on biosimilarity is analytically justified because a CMO 483 that maps to the NDA CMC module put disproportionate reporting signal workbook in play. Pharmacovigilance work in an RWE group proposing a post-marketing study instead of a new RCT now turns on biosimilarity is analytically justified because a CMO 483 that maps to the NDA CMC module put disproportionate reporting signal workbook in play; RWE evidence-strategy director should say what disproportionate reporting signal workbook proves for Pharma & Life Sciences.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• RWE evidence-strategy director can defend Proceed under protocol from disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge.
• RWE evidence-strategy director cannot defend Proceed under protocol from disproportionate reporting signal workbook; Pause the pathway is what the extract actually supports after a CMO 483 that maps to the NDA CMC module.
• A CMO 483 that maps to the NDA CMC module never reached the population in disproportionate reporting signal workbook — reopen intake, do not close biosimilarity is analytically justified.
• Two facts in disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module conflict for RWE evidence-strategy director; hold this Pharmacovigilance file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a CMO 483 that maps to the NDA CMC module and write the one fact that would move biosimilarity is analytically justified for RWE evidence-strategy director.